ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

China's Fosun to import 7.2m doses of BioNTech-Pfizer COVID vaccine

Company working with airlines to start shipments in January

Fosun is arranging logistics with several airlines to start transporting the vaccine from BioNTech’s German factory to China starting in January.    © Reuters

BioNTech's Chinese partner Shanghai Fosun Pharmaceutical Group plans to import 7.2 million doses of the German company's COVID-19 vaccine in the first half of 2021, Caixin learned from several people familiar with the company's plan.

Fosun is arranging logistics with several airlines to start transporting the vaccine from BioNTech's German factory to China starting in January. Based on available data, the company can import 1.2 million doses a month, the people said.

Insiders at Fosun said the data is not accurate, and it may only reflect the capability request some carriers received rather than the actual volume.

The coronavirus vaccine jointed developed by BioNTech and Pfizer, which was 95% effective in clinical trials, passed a critical milestone Thursday when a panel of experts formally recommended that the U.S. Food and Drug Administration authorize the vaccine.

China's own COVID-19 vaccines, developed by Sinopharm unit China National Biotec Group and CanSino Biologics, have already been administered to hundreds of thousands of people under emergency authorization in China, but they are yet to receive public use approval from any drug regulators. China National Biotec's vaccine was 86% effective in trials conducted in the United Arab Emirates, according to a state media report, which cited the country's Ministry of Health and Prevention.

Fosun secured rights from BioNTech in March to market the vaccine across the Chinese mainland, Hong Kong, Macao and Taiwan. The Chinese company said in August it intends to supply 10 million doses for Hong Kong and Macao, distributing them through Hong Kong's Jacobson Pharma Corp.

Under the deal with BioNTech, Fosun is also responsible for seeking approval of the vaccine from regulators in mainland China and Hong Kong. Fosun is getting ready to submit paperwork to drug regulators in Hong Kong for review as soon as next week, Bloomberg reported Friday, citing people familiar with the matter. The company has yet to apply for authorization on the mainland.

BioNTech told Caixin earlier that the vaccine intended for the China market will be produced at its facility in Marburg, Germany, but Fosun has been pushing to make it in China.

Fosun signed a deal in March to pay BioNTech as much as $135 million in upfront and "potential future investment and milestone" payments for exclusive commercialization rights in the Chinese mainland, Hong Kong, Macao and Taiwan. The Chinese partner will be responsible for marketing and sales costs and will get 65% of gross profits.

Fosun said in the future it might negotiate with BioNTech the possibility of manufacturing and packaging the vaccine in China, and it's communicating with the National Medical Products Administration on the matter.

As the vaccine requires ultra-cold temperatures in storage and transportation, Fosun said it has invested in ultra-cold storage facilities near Shanghai Pudong Airport with the capability to store the vaccine at -94 degrees Fahrenheit (-70 degrees Celsius). Refrigeration equipment provider Moon Environment Technology Co. Ltd. was contracted to build the storage facilities. At -94 degrees Fahrenheit, the vaccine can be kept for as long as 15 days.

Sinopharm Group will be responsible for providing cold chain distribution in China, Fosun said.

--

Read also the original story.

Caixinglobal.com is the English-language online news portal of Chinese financial and business news media group Caixin. Nikkei recently agreed with the company to exchange articles in English.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more